Aptus Pharma Board Approves Authorized Capital Increase and...
26 Mar 2026
CCME Global Limited (formerly known as genesis ibrc India Limited) has successfully completed a significant preferential allotment of equity shares, raising substantial capital from a diverse group of investors. The company's Preferential Issue Committee approved the allotment during a meeting held on March 26, 2026.
Allotment Details
The company allotted 3,22,50,000 fully paid-up equity shares with a face value of INR 10 each at par, generating total proceeds of INR 32,25,00,000. The allotment was made through a preferential issue on a private placement basis to 11 investors, comprising both promoters and non-promoters.
Parameter: Details Total Shares Allotted: 3,22,50,000 Face Value per Share: INR 10 Issue Price: INR 10 (at par) Total Amount Raised: INR 32,25,00,000 Number of Investors: 11
Investor Composition
The allotment was distributed among promoters and non-promoters, with the largest allocation going to promoter Mr. Padmanaban Krishnamoorthy.
Investor Name: Shares Allotted Category Mr. Padmanaban Krishnamoorthy: 2,00,00,000 Promoter / Individual Ms. V. Varalakshmi: 40,00,000 Promoter / Individual Mr. Noor Muhammed Habibullah: 20,00,000 Non-Promoter / Individual Mr. Suresh Kumar Ramani: 20,00,000 Non-Promoter / Individual Mr. Vidhu Mohan Pillai: 20,00,000 Non-Promoter / Individual Dhanesh Advisory LLP: 11,00,000 Non-Promoter / Body Corporate Mr. Kaushal Ruparel: 7,00,000 Non-Promoter / Individual Mr. Ajay Sangani: 2,00,000 Non-Promoter / Individual Mr. Nandlal Chaturvedi: 1,00,000 Non-Promoter / Individual Mr. Ravindranath Rajaram: 1,00,000 Non-Promoter / Individual Ms. Poonam Chaturvedi: 50,000 Non-Promoter / Individual
Impact on Share Capital
The preferential allotment has significantly enhanced the company's capital structure. The issued, subscribed and paid-up capital has increased substantially following this allotment.
Capital Structure: Before Allotment After Allotment Number of Shares: 1,30,00,000 4,52,50,000 Value (INR): 13,00,00,000 45,25,00,000
Regulatory Compliance
The allotment was conducted in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Companies Act, 2013, and related rules. The issue price of INR 10 was determined based on a valuation report issued by an Independent Registered Valuer dated January 28, 2026.
The newly allotted equity shares rank pari passu with existing equity shares in all respects, including dividend payment and voting rights. This allotment represents a partial subscription of the originally proposed 4,02,50,000 equity shares that were approved by shareholders through postal ballot on March 5, 2026.
Genesis IBRC India Limited has received in-principle approval from BSE Limited for a preferential issue of equity shares worth ₹40.25 crore. The company announced this significant corporate development on March 13, 2026, marking a key milestone in its capital raising initiative.
BSE Approval Details
The approval was granted through BSE's letter reference number LOD/PREF/GB/FIP/1863/2025-26 dated March 12, 2026. The exchange has provided its consent for the company to proceed with the preferential issue under Regulation 28 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Parameter: Details Total Shares: 4,02,50,000 equity shares Par Value: ₹10 per share Issue Size: ₹40.25 crore Allottees: Promoters and non-promoters Approval Date: March 12, 2026
Regulatory Compliance Requirements
BSE has outlined comprehensive compliance requirements that Genesis IBRC must fulfill for the successful completion of this preferential issue. The company must ensure strict adherence to multiple regulatory frameworks including the Companies Act 2013, Securities Contracts (Regulation) Act 1956, SEBI Act 1992, and the Depositories Act 1996.
The exchange has specifically emphasized compliance with:
Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Listing Agreement provisions signed with BSE
Internal Controls and Monitoring
BSE has advised Genesis IBRC to strengthen internal controls to monitor trades executed by proposed allottees in the company's scrip before allotment. The company must obtain undertakings from allottees confirming they will not engage in intra-day trading or sell company shares until the allotment date, as required under SEBI ICDR Regulations.
Key monitoring requirements include:
Verification of allottee compliance with trading restrictions
Ensuring adherence to Regulation 167(6) of SEBI ICDR Regulations 2018
Understanding that non-compliance may impact share listing
Post-Issue Formalities and Timeline
Following the allotment of securities, Genesis IBRC must submit a listing application without delay, along with applicable fees, in accordance with Regulation 14 of the LODR Regulations. The company has been specifically notified that it must apply for listing within twenty days from the date of allotment, as per Schedule XIX – Para (2) of ICDR Regulations and SEBI circular dated June 21, 2023.
Non-compliance with the twenty-day timeline will attract penalties as specified in the relevant SEBI circular. BSE reserves the right to withdraw this in-principle approval if any submitted information is found to be incomplete, incorrect, misleading, or in contravention of applicable regulations.
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.
